Finerenone - Bayer HealthCare Pharmaceuticals
Alternative Names: BAY-94-8862; Firialta™; KERENDIA; KerendiaLatest Information Update: 06 Sep 2024
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Amides; Antihyperglycaemics; Heart failure therapies; Naphthyridines; Nitriles; Small molecules; Urologics
- Mechanism of Action Mineralocorticoid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Diabetic nephropathies
- Phase III Chronic heart failure; Heart failure; Renal failure; Type 1 diabetes mellitus
Most Recent Events
- 06 Sep 2024 Bayers plans a meeting with the US FDA to discuss clinical data
- 01 Sep 2024 Bayer plans to submit applications for marketing authorization to the US FDA for finerenone for Heart failure
- 01 Sep 2024 Adverse events and efficacy data from a phase III FINEARTS-HF trial for Heart failure released by Bayer